Systemic mastocytosis is a myeloid neoplasm characterized by abnormal growth and accumulation of neoplastic mast cells in one or more organ systems. [1] [2] [3] Indolent and aggressive variants of systemic mastocytosis occur. 4, 5 So-called B and C findings have been defined to sub-classify systemic mastocytosis. 4 The latter include organopathies especially of bone marrow, liver, and bone because of mast cell infiltration and is indicative of aggressive systemic mastocytosis. The former include a high mast cell burden (420% mast cells in the bone marrow; serum tryptase 4200 ng/ml; organomegaly) and signs of a spread of the disease into myeloid lineages (dysmyelopoiesis; KIT D816V in other myeloid lineages). In the presence of two B findings, a smouldering systemic mastocytosis is diagnosed. The absence of B and C findings usually indicates an indolent course. Mast cell leukemia, per definition, is diagnosed when neoplastic mast cells exceed 20% of nucleated cells in the bone marrow smear and/or 10% of nucleated cells in the peripheral blood. 6, 7 Patients with indolent systemic mastocytosis are either asymptomatic or suffer from skin lesions, mediator-related symptoms, or osteoporosis. Indolent systemic mastocytosis patients with a silent clinical course have a normal or near-normal life expectancy. [1] [2] [3] 5, [8] [9] [10] In contrast, patients with aggressive systemic mastocytosis or mast cell leukemia have a less favorable prognosis and show a poor response to conventional cytostatic drugs. 5, 8, 11 These patients are therefore candidates for experimental therapy [11] [12] [13] [14] and several attempts have been made to identify novel therapeutic targets in neoplastic mast cells. 5, 8, [12] [13] [14] In most patients with systemic mastocytosis, including both those with aggressive systemic mastocytosis/mast cell leukemia and those with indolent systemic mastocytosis, the transforming KIT mutation D816V can be detected. 5, 8, [15] [16] [17] [18] [19] [20] This mutation is associated with autonomous activation of the KIT receptor and is therefore considered to contribute to abnormal growth and survival of neoplastic mast cells in systemic mastocytosis. 21 As KIT D816V is detectable not only in aggressive systemic mastocytosis and mast cell leukemia but also in indolent systemic mastocytosis, 15, 19, 20 it is thought that additional pro-oncogenic pathways and markers trigger and are indicative of the aggressive disease variants, that is, aggressive systemic mastocytosis and mast cell leukemia. Unfortunately, such additional molecular markers and pathways have not yet been identified.
An important diagnostic approach in systemic mastocytosis is the immunophenotyping of neoplastic mast cells by flow cytometry and/or immunohistochemistry. [22] [23] [24] In contrast to other myeloid cells, mast cells co-express tryptase and KIT and can thus be detected easily in bone marrow sections by immunostaining. 22, 25 A key marker of mast cells in systemic mastocytosis is CD25 (Escribano et al 22 ; Sotlar et al 24 ) , which is expressed by neoplastic mast cells in almost all patients with systemic mastocytosis, whereas normal and reactive mast cells in non-mastocytic hematopoietic and non-hematopoietic disorders are usually CD25-negative. 24 The expression of CD25 has also been proposed as a minor diagnostic criterion for systemic mastocytosis. 6 However, CD25 expression in systemic mastocytosis is independent of the aggressiveness of the neoplasm and is thus not related to the systemic mastocytosis subtype. A number of other mast cell markers, such as CD9, CD63, CD68, and pSTAT5, are also expressed on and/or in neoplastic mast cells independent of the disease variant. 26, 27 Some of these markers may be expressed by mast cells at slightly higher or lower levels in aggressive systemic mastocytosis or mast cell leukemia compared with indolent systemic mastocytosis. 28 However, so far no robust immunological marker that would discriminate between the indolent and aggressive variants of systemic mastocytosis has been identified. The CD30 antigen, also known as Ki-1 antigen, is a member of the tumor necrosis factor receptor superfamily. 29, 30 A number of studies have shown that CD30 is expressed by neoplastic cells in a small and distinct spectrum of human neoplasms, including embryonal carcinoma, Hodgkin lymphoma, anaplastic large cell lymphoma, and in rare cases of extramedullary myeloid sarcoma. [30] [31] [32] In addition, CD30 may be expressed in activated lymphoid cells in the course of viral infection, for example, infectious mononucleosis. 33 With the exception of single cases of myeloid sarcoma, CD30 expression has not been reported in the context of myeloid neoplasms so far. We here report that CD30 is expressed by neoplastic mast cells in certain patients with systemic mastocytosis. CD30 expression was found to correlate with the subtype of systemic mastocytosis in that in most patients with high-grade systemic mastocytosis (aggressive systemic mastocytosis or mast cell leukemia) the majority of mast cells were CD30-positive, whereas in most patients with indolent systemic mastocytosis, the great majority of mast cells were found to be CD30-negative.
Patients and methods

Patients and Diagnoses
Immunohistochemical evaluation of CD30 expression in tryptase-positive mast cells was performed on bone marrow biopsies from a total of 61 patients with mastocytosis (45 patients with typical indolent systemic mastocytosis, 2 with smouldering systemic mastocytosis, 5 with aggressive systemic mastocytosis, 6 with mast cell leukemia, 3 with cutaneous mastocytosis) and 1 patient with monoclonal mast cell activation syndrome. Serum tryptase levels were available for about half of these patients (indolent systemic mastocytosis, n ¼ 26; smouldering systemic mastocytosis, n ¼ 2; aggressive systemic mastocytosis, n ¼ 2; mast cell leukemia, n ¼ 2, cutaneous mastocytosis, n ¼ 3; monoclonal mast cell activation syndrome, n ¼ 1; Table 1 ). The control group consisted of 15 patients with bone marrow mast cell hyperplasia, 15 with various myelogenous neoplasms other than systemic mastocytosis (chronic myeloid leukemia, n ¼ 2; primary myelofibrosis, n ¼ 4; polycytemia vera, n ¼ 1; myelodysplastic syndrome, n ¼ 4; chronic myelomonocytic leukemia, n ¼ 1; acute myeloid leukemia, n ¼ 3), 3 with Hodgkin lymphoma (2 patients with nodal involvement and 1 patient with medullary involvement), and 3 with testicular germ cell tumors (2 with embryonal carcinoma, 1 with seminoma). Molecular analysis for the assessment of CD30 mRNA expression was performed in 9 patients with systemic mastocytosis (indolent systemic mastocytosis, n ¼ 5; aggressive systemic mastocytosis, n ¼ 3; mast cell leukemia, n ¼ 1) and 13 patients without mastocytosis, 3 of which showed a marked increase in bone marrow mast cells. The latter included two patients with an unclassifiable myeloproliferative neoplasm with eosinophilia and one patient with a tumor-free bone marrow in Hodgkin lymphoma. Unfortunately, no results of molecular analyses regarding aberrations in PDGFRA, PDGFRB, or FGFR1 genes were available in the patients with the unclassifiable myeloproliferative neoplasms with eosinophilia. The remaining cases consisted of one patient with a myelodysplastic syndrome, two with plasma cell myeloma, one with medullary CD30 in advanced mastocytosis (Table 2 ). c The same patient was investigated at two time-points.
À, 'negative', o10% of MC express CD30. +, 'positive', 10-50% of MC clearly express CD30. ++, 'strongly positive', 450% of MC clearly express CD30.
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infiltrates of a diffuse large B-cell lymphoma, one with medullary infiltrates of Hodgkin lymphoma, two with nodal Hodgkin lymphoma, and three with testicular germ cell tumors (Table 2) . Routinely processed bone marrow trephine biopsy specimens, lymph node biopsies, and testicular biopsies were drawn from the archives of the Institutes of Pathology, University of Vienna, Vienna, Austria; University of Munich, Munich, Germany; and Klinikum Ansbach, Ansbach, Germany. All biopsy specimens had been fixed in 5% neutral-buffered ethanol-formaldehyde solution. In the Viennese patients, bone marrow aspirates were obtained and mononuclear cells were isolated for molecular analyses using Ficoll. Diagnoses were established according to the WHO classification.
6,7
Immunohistochemistry
Immunohistochemical investigations were performed on archival bone marrow trephine biopsies taken from the iliac crest after informed consent had been obtained from the patients. After formalinfixation, these specimens had been mildly decalcified overnight in edetic acid, and embedded in paraffin wax. Sections were cut at 3 mm and stained for CD30 by the indirect immunoperoxidase-staining technique as described elsewhere. 24 Diagnostic sections were stained with H&E, Giemsa, and for naphthol AS-D chloroacetate esterase. Immunohistochemical investigations for tryptase (mAb G3, 1:500, Santa Cruz Biotechnology, Santa Cruz, CA, USA), CD117, CD25 (Novocastra, New Castle, UK), and CD34 (QBEND10; Biocare, Walnut Creek, CA, USA) were performed with the avidin-biotin immunoperoxidase-staining technique and the Vectastain Universal ABC-AP Kit (Vector Laboratories, Burlingham, CA, USA). 25, 34 The anti-CD30 monoclonal antibody Ber-H2 (Dako, Glostrup, Denmark; working dilution: 1:20) was applied at room temperature overnight. The slides were then washed in tris-buffered saline, incubated in biotinylated goat anti-mouse IgG for 30 min at room temperature, washed in tris-buffered saline, and then exposed to biotin-peroxidase complex for 30 min. 3-Amino-9-ethylcarbazole (Sigma, St Louis, MO, USA) was employed as chromogen. All slides were counterstained in Mayer's Hemalaun and mounted in Aquatex. A semi-quantitative scoring system for CD30 was applied using the following categories: 'negative' (À), o10% of mast cells in tryptase-positive mast cell infiltrates express immunohistochemically detectable CD30; 'positive' ( þ ), 10-50% of mast cells clearly express CD30; 'strongly positive' ( þ þ ), 450% of mast cells clearly express CD30.
Quantification of CD30 Expression by TissueFAXS
CD30 expression in tryptase-positive mast cells of compact mast cell infiltrates was quantified objectively in serial bone marrow sections obtained from seven patients with indolent systemic mastocytosis and four patients with advanced systemic mastocy- tosis (two with smouldering systemic mastocytosis and two with aggressive systemic mastocytosis; one patient with aggressive systemic mastocytosis progressed to mast cell leukemia and was analyzed at two different points in time) using the TissueFAXS system (TissueGnostics, Vienna, Austria). 35, 36 In detail, mast cell infiltrates were identified in tryptase-stained bone marrow sections and scanned by Histo-FAXS. Expression of CD30 was examined on serial bone marrow sections using Histo-FAXS. Nucleated cells within mast cell infiltrates were defined by nuclear color and shape. The cytoplasm in these lesional cells was examined for the expression of tryptase and the co-expression of CD30 by Histo-FAXS. Both, spindle-shaped and round cells were included in the calculation. The mean intensity of antibody-staining reactions obtained was plotted against the Hemalaun mean intensity, and was expressed as percentage of all nucleated (Hemalaun-positive) cells in form of DotPlots and histograms.
Analysis of KIT Codon 816 Mutations
In 36 patients (Table 1 , patients 1-30, 50, 51, 55-58), mRNA extracted from isolated bone marrow mast cells was evaluated for the presence of KIT codon 816 point mutations, especially D816V, by RT-PCR and Hinf I digestion. 18 In the remaining 39 patients with mastocytosis formalin-fixed and paraffinembedded bone marrow biopsies were analyzed for the c-kit genotype by peptide nucleic acid-mediated PCR clamping and melting point analysis of amplification products as described previously. 37, 38 The human mast cell leukemia cell line HMC-1.2, which is known to display the KIT mutation D816V, served as a positive control. 21 HMC-1 cells were kindly provided by Dr Butterfield of the Mayo Clinic, Rochester, MN, USA.
Evaluation of CD30 mRNA Expression
Five sections were cut at 10 mm from blocks of formalin-fixed and paraffin-embedded tissues (Table 2) under RNAse-free conditions. The sections were deparaffinized and total RNA was isolated using the High Pure FFPE RNA Micro Kit (Roche Diagnostics, Mannheim, Germany). RNA quantity was measured on a NanoDrop ND-1000 spectrophotometer (Peqlab Biotechnologie, Erlangen, Germany). The isolated RNA was stored at À80 1C until further processing. In addition, mRNA from native HMC-1 cells was also analyzed. The 'Universal Probes Library' software was used for the design of the RT-PCR primers (https://www.roche-appliedscience.com).
Aliquots of 100-500 ng of total RNA were reverse transcribed with the M-MuLV reverse transcriptase (Roche Diagnostics) and random hexamere primers (Hexanucleotide Mix, Roche Diagnostics). In brief, RNA and primers were mixed in a total volume of 10 ml, denatured at 70 1C for 5 min, and then cooled on ice. Reverse transcription was performed by incubation at 37 1C for 1 h after the addition of 5 Â RT buffer, dNTPs (0.5 mM each), and reverse transcriptase (2 U/ml) in a final volume of 20 ml. The enzyme was inactivated by incubation for 10 min at 90 1C.
Amplification of 1.5 ml of template cDNA was carried out in a final volume of 15 ml containing 0.2 mM of each primer (Table 3 ) and 0.6 U AmpliTaq Gold DNA Polymerase (Applied Biosystems, USA). After initial denaturation for 5 min at 95 1C, 50 PCR cycles were performed with the following cycling conditions: denaturation at 95 1C for 30 s, annealing at 56 1C for 30 s, and elongation at 72 1C for 30 s. The final amplification cycle was completed by an elongation step at 72 1C for 10 min. PCR products were analyzed by electrophoresis on 2.5% agarose gels in 1 Â TBE Buffer and ethidium bromide staining.
Statistical Analysis
Fisher's exact test for 2 Â 2 contingency tables was used to test for differences in proportions on nominal variables. The Mann-Whitney U-test was applied to test for differences of medians of continuous variables in the analysis of TissueFAXS results between indolent systemic mastocytosis and smouldering systemic mastocytosis/aggressive systemic mastocytosis/mast cell leukemia and correlation between continuous variables (ie, CD30 vs serum tryptase) was determined with the nonparametric Spearman correlation coefficient. The significance level was set at 0.05. Statistical analysis of the data was performed with SPSS software, version 17.0 (SPSS, Chicago, IL, USA).
Results
Preferential Expression of CD30 in Advanced Subtypes of Mastocytosis
Immunohistochemcial investigation showed CD30 to be expressed in tryptase-positive mast cells in 23/61 (38%) patients with mastocytosis (patient 1, Table 1 was not included because of insufficient diagnostic criteria for mastocytosis). In bone marrow biopsies from patients with cutaneous mastocytosis, CD30 staining was completely 'negative' (À) in all Figure 1) . Interestingly, however, in one patient with mast cell leukemia who transformed to acute myeloid leukemia, mast cells were found to display only weak expression of CD30 (patient 58) and in another patient with mast cell leukemia, CD30 expression was not detectable (patient 62). In contrast to the high-grade mastocytoses, clear-cut expression of CD30 was found in only 12/45 (27%) of patients with indolent systemic mastocytosis, the largest group of patients in this study. In detail, nine patients displayed a 'positive' ( þ ) and three patients 'strongly positive' ( þ þ ) expression of CD30 in their bone marrow mast cells.
In the group of patients with systemic mastocytosis for whom both detailed bone marrow data and serum tryptase levels were available (n ¼ 36, patients 1-30, 50, 51, 55-58), there was a weak tendency toward CD30 positivity in patients with a marked increase in bone marrow mast cells (Z10% of nucleated cells; 7/13, 54%) as compared with those patients with low mast cell numbers (o10% of nucleated cells; 2/13, 15%) which, however, did not reach statistical significance (P ¼ 0.097). There was also no significant difference in CD30 expression between KIT D816V -positive (21/52, 40%) and KIT
D816V
-negative indolent systemic mastocytosis cases (2/6, 33%; P ¼ 1.0). However, when indolent systemic mastocytosis patients were stratified according to their serum tryptase levels 60% (6/10) of patients with serum tryptase levels Z50 ng/ml showed 'positive' ( þ ) or 'strongly positive' ( þ þ ) expression of CD30 by their bone marrow mast cells compared with only 19% (3/16) of indolent systemic mastocytosis patients with serum tryptase levels o50 ng/ml (P ¼ 0.046). The patient with monoclonal mast cell activation syndrome did not exhibit expression of CD30 by bone marrow mast cells. 
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In summary, a highly significant difference (Po0.001) in a clear-cut expression of CD30 in mast cells was found between patients with advanced systemic mastocytosis (11/13, 85%), and those with the indolent form of the disease (12/45, 27%). In addition, CD30 expression was significantly increased in patients with markedly elevated serum tryptase levels (Z50 ng/ml; P ¼ 0.008). In general, the high-grade mastocytoses, especially aggressive systemic mastocytosis and mast cell leukemia, presented with a stronger staining intensity for CD30 and a higher percentage of CD30-positive mast cells. In contrast, with only 3 (6%) exceptional cases of indolent systemic mastocytosis showing a strong CD30 staining, the vast majority of the 45 indolent systemic mastocytosis cases investigated presented with only a minority of mast cells stained weakly or not at all (Figures 1-3) .
The bone marrow mast cells in non-neoplastic conditions and various non-mastocytic myeloid neoplasms did not express immunohistochemically detectable amounts of CD30. The same was true for the seminoma investigated. As positive controls, neoplastic Hodgkin and Reed-Sternberg cells from patients with Hodgkin lymphoma and tumor cells from the two testicular embryonal carcinomas were found to strongly express CD30 (not shown).
Detection of CD30 by TissueFAXS
To confirm expression of CD30 in tryptase-positive mast cell infiltrates by a non-subjective method, TissueFAXS was applied in seven patients with indolent systemic mastocytosis and four patients with advanced systemic mastocytosis (ie, smouldering systemic mastocytosis, n ¼ 2; aggressive systemic mastocytosis, n ¼ 1; mast cell leukemia, n ¼ 1; see Table 1 ). The patients with aggressive systemic mastocytosis later progressed to mast cell leukemia and were analyzed at two time points. This confirmed the strong expression of CD30 in advanced systemic mastocytosis (staining intensity, mean 11.4, range 6.3-30.9), whereas in less advanced forms of systemic mastocytosis, mast cell infiltrates expressed lower levels of CD30 (staining intensity, mean 4.7, range 1.2-9; P ¼ 0.012; Figure  3a) . A highly significant positive correlation of CD30 expression and serum tryptase levels, as described above for indolent systemic mastocytosis, became obvious also for the TissueFAXS analysis of compact mast cell infiltrates in indolent systemic mastocytosis and aggressive systemic mastocytosis/mast cell leukemia (P ¼ 0.008; r ¼ 0.72; Figure 3b ).
Detection of CD30 Transcripts in Formalin-Fixed and Paraffin-Embedded Bone Marrow Biopsies in Mastocytosis
RT-PCR analysis was performed to confirm CD30 mRNA expression by neoplastic mast cells. For this purpose, randomly selected bone marrow biopsies were used, including various systemic mastocytosis subtypes (Table 2 , n ¼ 9) and 13 patients without mastocytosis with and without CD30-positive neoplasms.
In the latter group, in line with the immunohistochemical results, no CD30 transcripts were detectable in the three patients with markedly increased bone marrow mast cells. Two of these patients had unclassifiable myeloproliferative neoplasm and eosinophilia. Of note, one of patient presented with a marked increase in CD25-positive spindle-shaped mast cells. The third patient had a Hodgkin lymphoma and showed a marked increase in bone marrow mast cells in his tumor-free bone marrow. In addition, no CD30 transcripts were detected in the four bone marrow biopsies of patients with myelodysplastic syndrome (n ¼ 1), plasma cell myeloma (n ¼ 2), and diffuse large B-cell lymphoma (n ¼ 1; Table 2 ). In contrast, high levels of CD30 transcripts were detected in biopsies containing Hodgkin lymphomas (n ¼ 3) and embryonal carcinoma (n ¼ 2), neoplasms typically displaying immunohistochemically detectable expression of CD30. The seminoma was CD30-negative by both immunohistochemistry and nested RT-PCR.
Among the patients with mastocytosis detection of CD30 mRNA was found to vary ( Figure 4) . Although CD30 transcripts were detected in all four patients with aggressive systemic mastocytosis (patients 6-9, Table 2 ), they were found in only three of five patients with indolent systemic mastocytosis (patients 1, 2, and 4, Table 2 ). Interestingly, in only two of the three cases, mast cell expression of CD30 was also found by immunohistochemistry. The two biopsies without detectable CD30 transcripts were also negative by immunohistochemistry (patients 3 and 5, Table 2 ). In conclusion, there was a good correlation between CD30 expression as detected by immunohistochemistry and CD30 mRNA expression in formalin-fixed and paraffinembedded biopsies. As expected, CD30 mRNA was also detected in extracts obtained from HMC-1 cells (not shown).
Discussion
Only a few characteristic markers, including KIT D816V CD25, and CD2, are expressed by neoplastic mast cells in systemic mastocytosis and thus serve as diagnostic criteria. 20, 22, 24 As these 'diagnostic' markers are expressed by neoplastic mast cells in all systemic mastocytosis subtypes, they cannot be employed for differentiating between the variants of systemic mastocytosis in terms of grading of the disease. We here report that CD30, a member of the tumor necrosis factor receptor family, is expressed by neoplastic mast cells in most patients with highgrade systemic mastocytosis, whereas mast cells in the majority of patients with indolent systemic The finding that CD30 is a marker of neoplastic mast cells in high-grade systemic mastocytosis was unexpected because CD30 is otherwise expressed only in a limited number of neoplastic states. Therefore, further investigations were undertaken to confirm this finding by mRNA analysis. In line with the immunohistochemical findings, CD30 
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mRNA was clearly detectable in all investigated patients with CD30-positive immunohistochemistry, but was not detectable in normal/reactive bone marrow and non-mastocytic hematopoietic neoplasms. In this regard, it is noteworthy that in almost all patients with indolent systemic mastocytosis, a small population of CD30-positive cells, presumably mast cells, could be detected, even when the majority of CD25-positive neoplastic mast cells were CD30-negative. Interestingly, no CD30 transcripts were found in a case of unclassifiable myeloproliferative neoplasm and eosinophilia characterized by an increase in CD25-positive mast cells with atypical spindle-shaped morphology. Notably this case was wild-type at KIT codon 816.
The expression of CD30 in normal/reactive tissues is restricted to a few cell types. In fact, CD30 is only detectable in a small subset of lymphocytes, most probably proliferating T and B blasts. Among T cells, CD30 is considered to be expressed preferentially by helper T cells, especially Th2 cells. 30, 31, 33, 39, 40 In neoplastic states, CD30 is known to be expressed by transformed cells in Hodgkin lymphoma (Hodgkin and Reed-Sternberg cells), anaplastic large cell lymphoma, and embryonal carcinoma. By contrast, the CD30 ligand (CD30L/CD153) is detectable in a variety of cell types, including T cells, granulocytes, monocytes/macrophages, and a proportion of bone marrow precursor cells of various lineages. [41] [42] [43] The CD30 ligand is also expressed by Hodgkin and Reed-Sternberg cells, suggesting homotypic interactions and, possibly, autocrine growth regulation. It has recently been shown that mast cells express functional CD30L/CD153 and are the predominant CD30L-positive cells in Hodgkin lymphoma. 44 In addition, functional CD30L has also been demonstrated in almost all mast cells of the HMC-1 mast cell leukemia cell line. 44 Thus, the demonstration of the consistent expression of CD30 in the majority of neoplastic mast cells in aggressive variants of systemic mastocytosis may argue for possible interactions between CD30 and its ligand, CD153, in neoplastic mast cells. One possibility could be that CD30-CD153 interactions are involved in autocrine growth regulation. Such autocrine interactions via CD30 and its ligand have also been described in Hodgkin lymphoma. 45, 46 Whether CD30 signaling in neoplastic mast cells, like in anaplastic large cell lymphoma cells, triggers NF-kB-mediated increased survival needs to be addressed in further functional studies. 47 The immunohistochemical and molecular demonstration of expression of CD30 by mast cells predominantly in the aggressive variants of mastocytosis may have important consequences for patients with this disease in several respects. First, CD30 can now be regarded as a potential grading marker in systemic mastocytosis that may be useful in screening for advanced disease. In addition, it may be employed to estimate the risk of progression of systemic mastocytosis in future studies. However, it should be noted that CD30 expression was also found in some patients in whom the clinical course had remained stable and, vice versa, a few patients showed rapid progression although their mast cells were clearly CD30-negative. Thus, CD30 expression by the mast cells in systemic mastocytosis is not invariably linked to an adverse prognosis. There are also other interesting aspects and unresolved questions concerning CD30 in systemic mastocytosis. For example, the functional role of CD30 and its ligand in systemic mastocytosis remains speculative. In previous studies, soluble CD30 was detected in the culture supernatant of CD30-positive tumor cell lines and in the sera of patients with CD30-positive Hodgkin lymphoma and anaplastic large cell lymphoma. [48] [49] [50] In these patients, soluble CD30 levels were found to indicate a poor outcome. Whether sCD30 can be employed as a diagnostic or prognostic serum marker in patients with mastocytosis remains to be determined. It is also not known whether CD30 and the CD30 ligand have a role in the growth or survival of neoplastic mast cells. 
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Another interesting aspect is that several CD30-targeted therapeutic strategies have been developed, as reviewed by Hirsch et al. 51 One of these molecules, chimeric anti-CD30 monoclonal antibody, has already demonstrated potent antitumor activity for both Hodgkin lymphoma and anaplastic large cell lymphoma in a preclinical phase II study. 52 Whether CD30 can also serve as a potential target in advanced systemic mastocytosis remains unknown. The advantage of such therapy would be that expression of CD30 is limited to neoplastic cells and a few normal lymphocytes, leaving most normal tissues and stem cells unaffected.
In conclusion, the increased expression of CD30 in mast cells of the aggressive subtypes of systemic mastocytosis predicts an important role for this protein in the pathogenesis of the disease. In addition, CD30 may serve as an essential biomarker indicative of aggressive disease variants in systemic mastocytosis. Moreover, CD30 expression in mast cells in mastocytosis may be of value for disease monitoring and prognostication. Finally, it may be reasonable to evaluate CD30 as a potential target in systemic mastocytosis in future studies.
